Compares surgery with biologic drugs for narrowed intestines in Crohn's disease
Compares surgery and biologic drugs in adults with narrowing of the intestine from Crohn's disease.
Plain-language title generated from the registry record
Registry title: Surgery vs Biologics for Treating Stricturing CD--a RCT
Key facts
- Where
- Nanjing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT05421455, who can take part
Where in China
- Department of General Surgery, Jinling hosptal,Medical School of Nanjing UniversityNanjing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zhu Weiming
- Trial code
- NCT05421455
- Record updated
- 9 July 2026
- Original description
The management of stricturing Crohn's disease (CD) remains challenging. Although surgical resection may be the final way to solve it, the efficacy of biologics for symptomatic CD associated strictures was acceptable. In clinical practice, the chioce of treatment is particularly difficult. Therefore, a clinical trial of biologics versus surgery is needed to assess which one is prefered.Read full original descriptionShow less
Surgery Versus Biologics for Symptomatic Stricturing Crohn's Disease : an Open-label, Single-center, Randomized Controlled Trial
The management of stricturing Crohn's disease (CD) remains challenging. Although surgical resection may be the final way to solve it, the efficacy of biologics for symptomatic CD associated strictures was acceptable. In clinical practice, the chioce of treatment is particularly difficult. Therefore, a clinical trial of biologics versus surgery is needed to assess which one is prefered.
Inclusion: with intestinal obstructive symptoms; confirmed intestinal strictures; traditional drugs failed to induce remission; envidence of active bowel inflammation; inappropriate for EBD; acquirement of written informed consent of participant.
Exclusion: successful treatment with traditional drugs; penetrating disease; unsuccessful medical treatment of intestinal obstruction; complete obstruction; contraindication for biologics; short smaal bowel; suspicion of bowel tumor; no confirmed strictures; comitant severe disese of other system; obstructive symptoms under over 2 targets of biologics; participate other clinical research.